Online,

Boston,

MA,

USA,

ZIP: 00000

Phone:

Running virtually for the 5th year, the Neoantigen Based Therapies Summit is the only industry-focused meeting dedicated solely to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.

Join this exclusive community of over 300+ leading industry experts, and navigate three tracks of content, as we discuss how to maximise immunogenicity, and streamline manufacturing processes to improve the clinical and commercial development of neoantigen based immunotherapies.

Earlybird and group discount rates are available. Visit the website to learn more: https://ter.li/qkclud

Prices:
Conference + Bootcamp: Book by August 7: USD 2622.0,
Conference + Bootcamp : USD 2937.0,
Conference + 2 Workshops: Book by August 7: USD 2622.0,
Conference + 2 Workshops: USD 2937.0,
Conference + 1 Workshop: Book by August 7: USD 2133.0,
Conference + 1 Workshop : USD 2488.0,
Conference Only: Book by August 7: USD 1644.0,
Conference Only: USD 1959.0

Speakers: Sijme Zeilemaker, Chief Operating Officer, Immunicum, Lei Zheng, Professor, John Hopkins School of Medicine, TJ Langer, Chief Executive Officer and President, Myst Therapeutics, Marit van Buuren, Director, T-cell Immunology,  Neon Therapeutics, Nicolas Poirier, Chief Scientific Officer, OSE Immunotherapeutics, Eric Halioua, President and Chief Executive Officer,  PDC*line Pharma, Jessica Fletchner, Chief Scientific Officer, Genocea, Narinder Singh, Senior Vice President, Pharmaceutical Sciences and Manufacturing,  Genocea, Raymond Miller, Senior Global Product Manager, Therapeutic Materials, GenScript Biotech Corporation, Gerben Zondag, Chief Executive Officer, Immunetune, Peter Joyce, Chief Executive Officer, Co-Founder, Grey Wolf Therapeutics, Thomas Davis, Chief Medical Office,  Genocea Biosciences, Gad Berdugo, Chief Executive Officer and Co-Founder, EpiVax Oncology, Inc., Guilhem Richard, Lead Computational Immunologist, EpiVax Oncology, Peter Mason, Head of Product Platform Science and Technology, Ervaxx Ltd, Jennie Lill, Senior Director of Proteomics and NGS, Genentech, Ingunn Stromnes, Assistant Professor, University of Minnesota, Scott Burkholz, Bioinformatics Scientist, Flow Pharma, Jens Kringelum, Director, Genomic Immuno-Oncology, Exaxion Biotech, Edward Samuel, SVP Manufacturing, Achilles Therapeutics, Chris Diehnelt, Associate Research Professor, Arizona State University, David Reardon, Clinical Director, Center for NeuroOncology, Dana-Farber Cancer Institute, Julie Rumble, Manager, Immunology Contract Services, Cayman Chemical, Tamara Ouspenskaia, Postdoctoral Fellow, Broad Institute, Marc Wolfgang, Vice President of Technical Operations, Neon Therapeutics, Niranjan Sardesai, Chief Executive Officer, Geneos Therapeutics, Thomas Wickham, Senior Vice President, Discovery, Rubius Therapeutics, Kaidre Bendjama, Project Leader, Personalized Cancer Vaccines,  Transgene, Heinz Lubenau, Chief Operating Officer, Vaximm, Agnete Fredriksen, Chief Scientific Officer, Vaccibody, Willem-Jan Krebber, Chief Operating Officer, ISA Pharmaceuticals, Andrew Allen, Chief Executive Officer, Gritstone Oncology, Lelia Delamarre, Senior Scientist, Cancer Immunology Research, Genentech, Trevor Clancy, Chief Scientific Officer and Co-Founder, OncoImmunity, Trishul Shah, Director of Business Development, PolyPeptide Group, Sean Boyle Senior Director, Bioinformatics Applications, Personalis Inc